{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T02:15:54Z","timestamp":1775700954248,"version":"3.50.1"},"reference-count":33,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T00:00:00Z","timestamp":1542240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:p>Omadacycline is a novel aminomethylcycline approved for the treatment of community\u2010acquired bacterial pneumonia and acute bacterial skin and skin structure infections. This article reviews existing data pertaining to the biochemistry, mechanism of action, pharmacokinetics\/pharmacodynamics, in\u00a0vitro activity, and current progress with omadacycline in clinical trials. Omadacycline inhibits protein synthesis by binding to the 30S subunit of the bacterial ribosome at the tetracycline\u2010binding site with an affinity similar to glycylcyclines. It is able to bypass older tetracycline resistance mechanisms and demonstrates activity against bacterial strains that are tetracycline resistant. In addition, omadacycline displays broad\u2010spectrum activity against gram\u2010positive organisms (including methicillin\u2010resistant <jats:italic>Staphylococcus aureus<\/jats:italic> and vancomycin\u2010resistant enterococci), gram\u2010negative organisms, atypical organisms, and anaerobes. It has been evaluated against infections in adults both intravenously and orally. Dosage adjustments are not required for patients with renal impairment. Omadacycline displays a comparable efficacy and safety profile to standard\u2010of\u2010care agents, with the most common side effects observed being gastrointestinal. Currently available data for omadacycline suggest that this is a promising agent added to our antimicrobial armamentarium.<\/jats:p>","DOI":"10.1002\/phar.2185","type":"journal-article","created":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T06:05:58Z","timestamp":1538805958000},"page":"1194-1204","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Omadacycline Enters the Ring: A New Antimicrobial Contender"],"prefix":"10.1002","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-3111","authenticated-orcid":false,"given":"Katie E.","family":"Barber","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice University of Mississippi School of Pharmacy Jackson Mississippi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison M.","family":"Bell","sequence":"additional","affiliation":[{"name":"Division of Pharmacy Practice and Administrative Sciences University of Cincinnati James L. Winkle College of Pharmacy Cincinnati Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Joyce B.","family":"Wingler","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services University of Mississippi Medical Center Jackson Mississippi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6006-7894","authenticated-orcid":false,"given":"Jamie L.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice University of Mississippi School of Pharmacy Jackson Mississippi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8635-0137","authenticated-orcid":false,"given":"Kayla R.","family":"Stover","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice University of Mississippi School of Pharmacy Jackson Mississippi"},{"name":"Department of Medicine Division of Infectious Diseases University of Mississippi Medical Center Jackson Mississippi"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,11,15]]},"reference":[{"key":"e_1_2_12_2_1","first-page":"e1403","article-title":"A review on antibiotic resistance: alarm bells are ringing","volume":"9","author":"Zaman SB","year":"2017","journal-title":"Cureus"},{"key":"e_1_2_12_3_1","unstructured":"Centers for Disease Control and Prevention.Pneumonia.https:\/\/www.cdc.gov\/nchs\/fastats\/pneumonia.htm. Accessed April 18 2018."},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-252"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01242-13"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01536-15"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2016.07.029"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01066-13"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02327-17"},{"issue":"12","key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1128\/AAC.01734-16","article-title":"In vitro activities of omadacycline (PTK 0796) and other antimicrobial agents against human mycoplasmas and ureaplasmas","volume":"60","author":"Waites KB","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00609-17"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.01.019"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00047-18"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02551-17"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02434-16"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2016-0100"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics5040032"},{"issue":"2","key":"e_1_2_12_18_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01487-17","article-title":"Safety and pharmacokinetics of the aminomethylcycline antibiotic omadacycline administered to healthy subjects in oral multiple\u2010dose regimens","volume":"62","author":"Bundrant LA","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"7431","DOI":"10.1128\/AAC.01393-16","article-title":"Randomized, open\u2010label study of the pharmacokinetics and safety of oral and intravenous administration of omadacycline to healthy subjects","volume":"60","author":"Sun H","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2016.1213465"},{"issue":"2","key":"e_1_2_12_21_1","first-page":"1","article-title":"Pharmacokinetics and safety of omadacycline in subjects with impaired renal function","volume":"62","author":"Berg JK","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.814"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01135-17"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl224"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02368-16"},{"key":"e_1_2_12_26_1","doi-asserted-by":"crossref","unstructured":"StetsR PopescuM GonongJ et\u00a0al.A phase 3 randomized double\u2010blind multi\u2010center study to compare the safety and efficacy of moxifloxacin for the treatment of adult patients with CABP (the OPTIC study). ID Week 2017; 2017 Oct 4\u20138; San Diego CA. Poster 1883. 2017.","DOI":"10.1093\/ofid\/ofx163.1413"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00948-12"},{"key":"e_1_2_12_28_1","unstructured":"Paratek.A phase 3 randomized double\u2010blind multi\u2010center study to compare the safety and efficacy of oral and IV omadacycline to linezolid for treating adult subjects with ABSSSI (The OASIS Study). 2017 Apr 24. Available fromhttps:\/\/paratekpharma.com\/media\/1410\/eccmid-oasis-oral-final-22apr2017-vff.pdf. Accessed May 31 2018."},{"key":"e_1_2_12_29_1","unstructured":"Paratek.ABSSSI\u201016301 study design: top\u2010line data results. Omadacycline in acute skin and skin structure infections study (OASIS\u20102). 2017 Jul 17. Available fromhttp:\/\/paratekpharma.com\/media\/1462\/final-top-line-16301-absssi-17-July-2017-v1-investor-presentation.pdf. Accessed May 31 2018."},{"key":"e_1_2_12_30_1","volume-title":"Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment","author":"FDA Center for Drug Evaluation and Research (CDER)","year":"2010"},{"key":"e_1_2_12_31_1","doi-asserted-by":"crossref","unstructured":"WilcoxM Cure\u2010BoltN ChitraS TzanisE McGovernP.Efficacy and safety of omadacycline in patients with acute bacterial skin and skin structure infections (ABSSSI) and high body mass index or diabetes: a subgroup analysis from the OASIS trial. Poster session presented at: ID Week 2017; 2017 Oct 4\u20138; San Diego CA. Available fromhttp:\/\/paratekpharma.com\/media\/1489\/wilcoxidweek20171838omc-oasis-1-bmi-dm.pdf. Accessed May 31 2018.","DOI":"10.1093\/ofid\/ofx163.1368"},{"key":"e_1_2_12_32_1","doi-asserted-by":"crossref","unstructured":"FileTMJr Cure\u2010BoltN ChitraS TzanisE McGovernP.Efficacy and safety of omadacycline in chronic kidney disease (CKD) patients with acute bacterial skin and skin structure infections (ABSSSI): a subgroup analysis from the OASIS trial. Poster session presented at: ID Week 2017; 2017 Oct 4\u20138; San Diego CA. Available fromhttps:\/\/paratekpharma.com\/media\/1490\/fileidweek20171834omc-oasis-1-ckd.pdf. Accessed May 31 2018.","DOI":"10.1093\/ofid\/ofx163.1364"},{"key":"e_1_2_12_33_1","doi-asserted-by":"crossref","unstructured":"OhlCA Cure\u2010BoltN ChitraS TzanisE McGovernP.Efficacy and safety of omadacycline in intravenous drug using (IVDA) and hepatitis C\u2010positive (HCV+) patients with acute bacterial skin and skin structure infections (ABSSSI): a subgroup analysis from the OASIS trial. Poster session presented at: ID Week 2017; 2017 Oct 4\u20138; San Diego CA. Available fromhttps:\/\/paratekpharma.com\/media\/1485\/ohlidweek20171885omc-oasis-1-ivdu.pdf. Accessed May 31 2018.","DOI":"10.1093\/ofid\/ofx163.1415"},{"key":"e_1_2_12_34_1","doi-asserted-by":"crossref","unstructured":"DarpoB TzanisBA Garrity\u2010RyanL et\u00a0al.Cardiac safety of omadacycline in the IV\/oral phase 3 acute bacterial skin and skin structure (ABSSSI) and in the IV\/oral phase 3 community\u2010acquired bacterial pneumonia (CABP) studies. ID Week 2017; 2017 Oct 4\u20138; San Diego CA. Available fromhttps:\/\/paratekpharma.com\/media\/1486\/darpoidweek20171886omc-cardiac-safety-oasis-1-optic.pdf. Accessed May 31 2018.","DOI":"10.1093\/ofid\/ofx163.1416"}],"updated-by":[{"DOI":"10.1002\/phar.2226","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,2,3]],"date-time":"2019-02-03T00:00:00Z","timestamp":1549152000000}},{"DOI":"10.1002\/phar.2363","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,1,5]],"date-time":"2020-01-05T00:00:00Z","timestamp":1578182400000}}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.2185","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2185","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2185","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:55:02Z","timestamp":1761051302000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,15]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1002\/phar.2185"],"URL":"https:\/\/doi.org\/10.1002\/phar.2185","archive":["Portico"],"relation":{"correction":[{"id-type":"doi","id":"10.1002\/phar.2226","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/phar.2363","asserted-by":"object"}]},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,15]]},"assertion":[{"value":"2018-11-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}